Performance of 3 Sampling Methods for the Detection of SARS-CoV-2 (COVID-19) With Real-time Reverse Transcriptase PCR
NCT ID: NCT04361448
Last Updated: 2021-02-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
30 participants
INTERVENTIONAL
2020-04-20
2020-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
COVID-19: SARS-CoV-2 Detection in Saliva, Oropharyngeal and Nasopharyngeal Specimens
NCT04715607
Dry Versus Wet Nasopharyngeal Rapid Test for the Detection of COVID-19.
NCT04839094
Diagnostic Performance Evaluation of a Novel SARS-CoV-2 (COVID-19) Antigen Detection Test
NCT04609969
Impact of Swab Site and Sample Collector on Testing Sensitivity for COVID-19 Virus in Symptomatic Individuals
NCT04321369
COVIDISC: Rapid Diagnostic Tests on Nasopharyngeal Swabs for the Detection of COVID-19
NCT04703140
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
For each volunteer, 3 swabs will be taken:
* Flocked eSwab (Copan, Italy) of the oropharynx
* Flocked nasopharyngeal eSwab (Copan, Italy) of the nasopharynx
* Dry flocked nasopharyngeal Swab, placed in lysis buffer Each swab will be tested for the presence of SARS-CoV-2 with an in-house reverse-transcriptase real-time PCR (Egene).
Performance of each method will be calculated.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Health Care Workers with Covid-19 symptoms
3 samples (2 nasopharyngeasl swabs, 1 oropharyngeal swab) willl be taken from each volunteer
samling of oropharynx and nasopharynx
Three different swabs will be taken of each participant: 1 oropharyngeal swab and 2 nasopharyngeal swabs
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
samling of oropharynx and nasopharynx
Three different swabs will be taken of each participant: 1 oropharyngeal swab and 2 nasopharyngeal swabs
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jessa Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Reinoud Cartuyvels
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Reinoud Cartuyvels
Role: PRINCIPAL_INVESTIGATOR
Jessa Hospital, Hasselt, Belgium
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Jessa Hospital
Hasselt, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20.43
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.